View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 4, 2020updated 12 Jul 2022 11:58am

STELLAR clinical trial of eflornithine to enrol brain tumour patients

UK-based charity commission Brain Tumour Charity has announced that the STELLAR trial, which will test the safety and efficacy of eflornithine, is now open for patients to enrol.

UK-based charity commission Brain Tumour Charity has announced that the STELLAR trial, which will test the safety and efficacy of eflornithine, is now open for patients to enrol.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Eflornithine is an oral regimen used to treat patients identified with recurring anaplastic astrocytoma.

The STELLAR trial is a Phase III clinical trial that aims to study oral eflornithine as a possible novel treatment for recurrent anaplastic astrocytoma.

Funded by Orbus Therapeutices, the trial is now open to eligible patients for enrolment across North America, Europe and selected sites in the UK.

The Brain Tumour Charity commission said in a statement: “Anaplastic astrocytoma brain tumours are most common in adults aged 30 to 50 years, although it can affect all ages if they recur after surgery, chemotherapy or radiotherapy there are currently few treatments available, something the STELLAR trial aims to investigate.”

This Phase III clinical trial is designed to show if eflornithine can inhibit malignant tumour growth, including intracerebral high-grade gliomas.

Under this trial, eflornithine will be administered orally and will target a key enzyme called ornithine decarboxylase. This enzyme plays a major role in the growth of cancer cells in the brain.

In 2014, eflornithine received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with anaplastic glioma.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena